Complement and the kidney: What the nephrologist needs to know in 2006?

Nephrology Dialysis Transplantation

Volumn 20, Issue 12, 2005, Pages 2613-2619

  Berger, Stefan P ^a   Roos, Anja ^a   Daha, Mohamed R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; MANNOSE BINDING LECTIN; MONOCLONAL ANTIBODY; TP 10; UNCLASSIFIED DRUG;

CLINICAL PRACTICE; CLINICAL TRIAL; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; COMPLEMENT LECTIN PATHWAY; COMPLEMENT SYSTEM; DIABETIC NEPHROPATHY; EDITORIAL; GLOMERULONEPHRITIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INNATE IMMUNITY; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHROLOGY; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; REPERFUSION INJURY; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TREATMENT PLANNING;

ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DISEASE PROGRESSION; HUMANS; IMMUNITY, NATURAL; KIDNEY DISEASES;

EID: 27944465737     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfi166     Document Type: Editorial

References (67)

1. Nauta AJ, Daha MR, van Kooten C, Roos A. Recognition and clearance of apoptotic cells: A role for complement and pentraxins. Trends Immunol 2003; 24: 148-154
2. Turner MW. The role of mannose-binding lectin in health and disease. Mol Immunol 2003; 40: 423-429
3. Adler S, Baker PJ, Johnson RJ et al. Complement membrane attack complex stimulates production of reactive oxygen metabolites by cultured rat mesangial cells. J Clin Invest 1986; 77: 762-767
4. Nauta AJ, Trouw LA, Daha MR et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 2002; 32: 1726-1736
5. Nauta AJ, Raaschou-Jensen N, Roos A et al. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol 2003; 33: 2853-2863
6. Nauta AJ, Castellano G, Xu W et al. Opsonization with C1q and mannose-binding lectin targets apoptotic cells to dendritic cells. J Immunol 2004; 173: 3044-3050
7. Botto M, Dell'Agnola C, Bygrave AE et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998; 19: 56-59
8. Paul E, Pozdnyakova OO, Mitchell E, Carroll MC. Anti-DNA autoreactivity in C4-deficient mice. Eur J Immunol 2002; 32: 2672-2679
9. Mitchell DA, Pickering MC, Warren J et al. C1q deficiency and autoimmunity: The effects of genetic background on disease expression. J Immunol 2002; 168: 2538-2543
10. Wang Y, Hu Q, Madri JA et al. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996; 93: 8563-8568
11. Bao L, Haas M, Boackle SA et al. Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol 2002; 168: 3601-3607
12. Seelen MA, Trouw LA, Daha MR. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 2003; 12: 619-624
13. Moroni G, Trendelenburg M, Del Papa N et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 2001; 37: 490-498
14. Trouw LA, Groeneveld TW, Seelen MA et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004; 114: 679-688
15. Miyazaki R, Kuroda M, Akiyama T et al. Glomerular deposition and serum levels of complement control proteins in patients with IgA nephropathy. Clin Nephrol 1984; 21: 335-340
16. Endo M, Ohi H, Ohsawa I et al. Glomerular deposition of mannose-binding lectin (MBL) indicates a novel mechanism of complement activation in IgA nephropathy. Nephrol Dial Transplant 1998; 13: 1984-1990
17. Roos A, Bouwman LH, Gijlswijk-Janssen DJ et al. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001; 167: 2861-2868
18. Zhou W, Farrar CA, Abe K et al. Predominant role for C5b-9 in renal ischaemia/reperfusion injury. J Clin Invest 2000; 105: 1363-1371
19. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 2003; 170: 1517-1523
20. Thurman JM, Lucia MS, Ljubanovic D, Holers VM. Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int 2005; 67: 524-530
21. de Vries B, Matthijsen RA, Wolfs TG et al. Inhibition of complement factor C5 protects against renal ischaemia-reperfusion injury: inhibition of late apoptosis and inflammation. Transplantation 2003; 75: 375-382
22. Walsh MC, Bourcier T, Takahashi K et al. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischaemia and reperfusion injury. J Immunol 2005; 175: 541-546
23. Hart ML, Ceonzo KA, Shaffer LA et al. Gastrointestinal ischaemia-reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol 2005; 174: 6373-6380
24. de Vries B, Walter SJ, Peutz-Kootstra CJ et al. The mannose-binding lectin-pathway is involved in complement activation in the course of renal ischaemia-reperfusion injury. Am J Pathol 2004; 165: 1677-1688
25. Moller-Kristensen M, Wang W, Ruseva M et al. Mannan-binding lectin recognizes structures on ischaemic reperfused mouse kidneys and is implicated in tissue injury. Scand J Immunol 2005; 61: 426-434
26. Feucht HE, Schneeberger H, Hillebrand G et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-1338
27. Collins AB, Schneeberger EE, Pascual MA et al. Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999; 10: 2208-2214
28. Bohmig GA, Exner M, Habicht A et al. Capillary Cd4 deposition in kidney allografts: A specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091-1099
29. Herzenberg AM, Gill JS, Djurdjev O, Magil AB. C4d deposition in acute rejection: An independent long-term prognostic factor. J Am Soc Nephrol 2002; 13: 234-241
30. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714
31. Arnold JN, Wormald MR, Suter DM et al. Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J Biol Chem 2005; 280: 29080-29087
32. Berger SP, Roos A, Mallat MJ et al. Association between mannose-binding lectin levels and graft survival in kidney transplantation. Am J Transplant 2005; 5: 1361-1366
33. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8: 582-587
34. Heeger PS, Lalli PN, Lin F et al. Decay-accelerating factor modulates induction of T cell immunity. J Exp Med 2005; 201: 1523-1530
35. Caprioli J, Bettinaglio P, Zipfel PF et al. The molecular basis of familial haemolytic uraemic syndrome: Mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001; 12: 297-307
36. Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME et al. Clustering of missense mutations in the C-terminal region of factor H in atypical haemolytic uraemic syndrome. Am J Hum Genet 2001; 68: 478-484
37. Warwicker P, Goodship TH, Donne RL et al. Genetic studies into inherited and sporadic haemolytic uraemic syndrome. Kidney Int 1998; 53: 836-844
38. Neumann HP, Salzmann M, Bohnert-Iwan B et al. Haemolytic uraemic syndrome and mutations of the factor H gene: A registry-based study of German speaking countries. J Med Genet 2003; 40: 676-681
39. Sanchez-Corral P, Gonzalez-Rubio C, Rodriguez DC, Lopez-Trascasa M. Functional analysis in serum from atypical haemolytic uraemic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol 2004; 41: 81-84
40. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41: E84
41. Noris M, Brioschi S, Caprioli J et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362: 1542-1547
42. Kavanagh D, Kemp EJ, Mayland E et al. Mutations in complement factor I predispose to development of atypical haemolytic uraemic syndrome. J Am Soc Nephrol 2005; 16: 2150-2155
43. Hsu SI, Couser WG. Chronic progression of tubulointerstitial damage in proteinuric renal disease is mediated by complement activation: A therapeutic role for complement inhibitors? J Am Soc Nephrol 2003; 14: S186-S191
44. Schulze M, Baker PJ, Perkinson DT et al. Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat. Kidney Int 1989; 35: 60-68
45. Schulze M, Donadio JV Jr, Pruchno CJ et al. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int 1991; 40: 533-538
46. Morita Y, Ikeguchi H, Nakamura J et al. Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol 2000; 11: 700-707
47. Nangaku M, Pippin J, Couser WG. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 1999; 10: 2323-2331
48. Nath KA, Hostetter MK, Hostetter TH. Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3. J Clin Invest 1985; 76: 667-675
49. Falk RJ, Sisson SP, Dalmasso AP et al. Ultrastructural localization of the membrane attack complex of complement in human renal tissues. Am J Kidney Dis 1987; 9: 121-128
50. Rosoklija GB, Dwork AJ, Younger DS et al. Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Neuropathol Berl 2000; 99: 55-62
51. Zhang J, Gerhardinger C, Lorenzi M. Early complement activation and decreased levels of glycosylphosphatidylinositol-anchored complement inhibitors in human and experimental diabetic retinopathy. Diabetes 2002; 51: 3499-3504
52. Qin X, Goldfine A, Krumrei N et al. Glycation inactivation of the complement regulatory protein CD59: A possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004; 53: 2653-2661
53. Hansen TK, Tarnow L, Thiel S et al. Association between mannose-binding lectin and vascular complications in type 1 diabetes. Diabetes 2004; 53: 1570-1576
54. Hovind P, Hansen TK, Tarnow L et al. Mannose-binding lectin as a predictor of microalbuminuria in type 1 diabetes: An inception cohort study. Diabetes 2005; 54: 1523-1527
55. Hebert LA, Cosio FG, Neff JC. Diagnostic significance of hypocomplementemia. Kidney Int 1991; 39: 811-821
56. Seelen MA, Roos A, Wieslander J et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods 2005; 296: 187-198
57. Bouwman LH, Roos A, Terpstra OT et al. Mannose binding lectin gene polymorphisms confer a major risk for severe infections after liver transplantation. Gastroenterology 2005; 129: 408-414
58. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res 2002; 4 [Suppl 3]: S279-S293
59. Trendelenburg M, Marfurt J, Gerber I, Tyndall A, Schifferli JA. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis Rheum 1999; 42: 187-188
60. Siegert CE, Daha MR, Tseng CM et al. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 1993; 52: 851-856
61. Quigg RJ. Use of complement inhibitors in tissue injury. Trends Mol Med 2002; 8: 430-436
62. Quigg RJ, He C, Lim A et al. Transgenic mice overexpressing the complement inhibitor crry as a soluble protein are protected from antibody-induced glomerular injury. J Exp Med 1998; 188: 1321-1331
63. Quigg RJ, Kozono Y, Berthiaume D et al. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor. J Immunol 1998; 160: 4553-4560
64. Couser WG, Johnson RJ, Young BA et al. The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis. J Am Soc Nephrol 1995; 5: 1888-1894
65. Pratt JR, Jones ME, Dong J et al. Nontransgenic hyperexpression of a complement regulator in donor kidney modulates transplant Ischaemia/ reperfusion damage, acute rejection, and chronic nephropathy. Am J Pathol 2003; 163: 1457-1465
66. Hill A, Hillmen P, Richards SJ et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood 2005; 106: 2559-2565
67. Hillmen P, Hall C, Marsh JC et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2004; 350: 552-559